BUZZ-MiNK Therapeutics rises after data shows long-lasting remissions in tough cancers

Reuters11-07
BUZZ-MiNK <a href="https://laohu8.com/S/LENZ">Therapeutics</a> rises after data shows long-lasting remissions in tough cancers

** Shares of drug developer MiNK Therapeutics INKT.O rise 2% to $13.93 premarket

** Co says its experimental cell therapy, agenT-797, shows lasting benefits for patients with advanced cancers who had stopped responding to other treatments

** INKT says patients who received agenT-797, either alone or with an existing immunotherapy drug, lived for a median of about 23 months

** Some patients with tough-to-treat cancers, including testicular, thymoma, and gastric cancers, saw their disease controlled for more than two years - co

** Doctors say that one patient with metastatic testicular cancer experienced a complete remission lasting over two years after receiving the combination therapy - INKT

** Other patients with different cancers also saw their tumors shrink or stop growing for extended periods, co says

** Up to last close, stock up 96% YTD

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment